Retatrutide Phase 3 Trials: What We Know So Far About the Triple Agonist's Clinical Path

Retatrutide — the triple GLP-1/GIP/glucagon receptor agonist from Eli Lilly — has moved into Phase 3 clinical development following striking Phase 2 results that showed weight loss of up to 24.2% at 48 weeks. Multiple Phase 3 programs are now underway, each targeting different patient populations and metabolic indications.

Phase 2 Recap: The Data That Started It All

The Phase 2 trial published in the New England Journal of Medicine randomized 338 adults with obesity to retatrutide or placebo at various doses. The highest dose group (12mg weekly) achieved mean weight loss of 24.2% at 48 weeks — a result that exceeded both semaglutide and tirzepatide's Phase 2 data at comparable timepoints. Perhaps more significantly, 100% of participants in the highest dose group lost at least 5% of their body weight, and 83% lost at least 15%.

Current Phase 3 Programs

Several Phase 3 trials are currently enrolling or underway. The TRIUMPH program encompasses multiple studies across obesity, type 2 diabetes, and metabolic complications. These large-scale trials will enroll thousands of participants and provide the definitive efficacy and safety data needed for regulatory submissions.

The Key Questions Phase 3 Will Answer

While Phase 2 data was impressive, several critical questions remain. How does retatrutide compare head-to-head against tirzepatide? Phase 2 comparisons are indirect — different trials, different populations, different protocols. Direct comparison data is needed. What are the long-term cardiovascular outcomes? GLP-1 agonists have demonstrated cardiovascular benefit, but the glucagon component adds complexity. And what happens with long-term use — does efficacy sustain, plateau, or decline?

Liver Health Data

One of the most anticipated Phase 3 datasets involves retatrutide's effects on non-alcoholic fatty liver disease (NAFLD/NASH). Phase 2 data showed dramatic reductions in liver fat content — exceeding results from any other incretin-based therapy. If Phase 3 confirms these findings, retatrutide could become the first approved treatment specifically targeting metabolic liver disease, a condition affecting 25% of the global population.

Timeline and Expectations

Phase 3 data readouts are expected beginning in late 2026 through 2027. If successful, regulatory submissions could follow in 2027-2028. The path from Phase 3 data to market availability typically takes 1-2 years, meaning retatrutide could potentially reach patients by 2028-2029 — assuming the Phase 3 data supports the promise of Phase 2.

We'll continue tracking retatrutide's clinical development and publish updates as new data becomes available. Create an account to get alerts when new articles are published.